OncoMatch/Clinical Trials/NCT05583071

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Is NCT05583071 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Tafasitamab and Lenalidomide for non-hodgkin lymphoma.

Phase 2RecruitingUniversity of CologneNCT05583071Data as of May 2026

Treatment: Tafasitamab · Lenalidomide · Rituximab · Methotrexate — Pilot-trial of Methotrexate, Tafasitamab (Minjuvi®), Lenalidomide (Revlimid®) and Rituximab in patients ineligible for HCT-ASCT with Primary Central Nervous System Lymphoma (PCNSL)

Check if I qualify

Extracted eligibility criteria

Cancer type

Non-Hodgkin Lymphoma

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: any treatment for PCNSL

Exception: pre-phase treatment comprising steroid treatment and/or single application of rituximab 375 mg/m² and methotrexate 3.5 g/m²

Prior treatment for PCNSL with the exception of a pre-phase treatment comprising steroid treatment and / or single application of rituximab 375 mg/m² and methotrexate 3.5 g/m²

Lab requirements

Blood counts

white blood cell (wbc) count ≥ 3000/µl or absolute neutrophil count (anc) ≥ 1000/µl; platelets ≥ 50.000/µl; hemoglobin > 8.0 g/dl

Kidney function

serum creatinine estimated glomerular filtration rate (mdrd) ≥ 50 ml/min

Liver function

alat and asat ≤ 3 uln; bilirubin ≤ 2.0 mg/dl (except for meulengracht disease)

Cardiac function

cardiac ejection fraction ≥ 40%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify